戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 l carcinoma undergoing radiotherapy alone or concurrent chemoradiotherapy.
2 nts undergoing radiotherapy or sequential or concurrent chemoradiotherapy.
3 e consistent with toxicities associated with concurrent chemoradiotherapy.
4 early postoperative chemotherapy followed by concurrent chemoradiotherapy.
5 on chemotherapy did not preclude delivery of concurrent chemoradiotherapy.
6 o achieved more than 50% response went on to concurrent chemoradiotherapy.
7  radiotherapy and first-line chemotherapy or concurrent chemoradiotherapy.
8 or patients with stage III lung cancer after concurrent chemoradiotherapy.
9 ients with stage II/III NSCLC ineligible for concurrent chemoradiotherapy.
10 poor survival outcomes even after aggressive concurrent chemoradiotherapy.
11 emoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients).
12 and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-dail
13 cause of irAEs, all of which occurred during concurrent chemoradiotherapy; 98.3% of patients complete
14    The addition of induction chemotherapy to concurrent chemoradiotherapy added toxicity and provided
15 ous 6 months, and/or who were ineligible for concurrent chemoradiotherapy after oncology consultation
16 rrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with loca
17 rapy with either docetaxel or carboplatin or concurrent chemoradiotherapy alone with two cycles of bo
18 xicity and provided no survival benefit over concurrent chemoradiotherapy alone.
19 ive, late stage (III and IV), receiving both concurrent chemoradiotherapy and induction/adjuvant chem
20 nt studies have suggested the superiority of concurrent chemoradiotherapy and the efficacy of paclita
21 atients did not receive more than 2 weeks of concurrent chemoradiotherapy and were not assessable for
22 ve a role for patients who initially receive concurrent chemoradiotherapy, and further study in this
23 ntified, and this has led to the adoption of concurrent chemoradiotherapy as a standard of care for t
24 ith the anti-PD-L1 antibody durvalumab after concurrent chemoradiotherapy as the standard-of-care app
25 ith advanced T-stage OPSCC who had completed concurrent chemoradiotherapy, bioradiotherapy, or radiot
26 DEVD-S-DOX could be an efficient prodrug for concurrent chemoradiotherapy by selectively delivering d
27                        Given the toxicity of concurrent chemoradiotherapy, careful selection of patie
28                                 Taxane-based concurrent chemoradiotherapy (CCR) for head and neck can
29 he impact of induction chemotherapy (IC) and concurrent chemoradiotherapy (CCR).
30  PET/CT scan before adjuvant radiotherapy or concurrent chemoradiotherapy (CCRT) could meaningfully i
31                                              Concurrent chemoradiotherapy (CCRT) for squamous cell ca
32 hibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced
33                                              Concurrent chemoradiotherapy (CCRT) prevented involvemen
34  oesophageal cancer (EC) patients undergoing concurrent chemoradiotherapy (CCRT) remains uncertain.
35 neck squamous cell carcinoma (LAHNSCC) after concurrent chemoradiotherapy (CCRT).
36 ll-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT).
37 cancer (NSCLC) without progression following concurrent chemoradiotherapy (cCRT).
38  69% to 88%) after treatment with definitive concurrent chemoradiotherapy (CRT) after IC and 54% (95%
39 ies have demonstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced
40 ely analyzed 162 OPSCC patients treated with concurrent chemoradiotherapy, equally divided into separ
41                   Many patients treated with concurrent chemoradiotherapy exhibit a decline in neutro
42                Neoadjuvant camrelizumab plus concurrent chemoradiotherapy exhibits promising patholog
43 ced non-small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durval
44 ncer (NSCLC) patients undergoing neoadjuvant concurrent chemoradiotherapy followed by surgery (trimod
45 zumab (200 mg) or placebo every 3 weeks with concurrent chemoradiotherapy, followed by 15 cycles of p
46 d safety of palifermin in patients receiving concurrent chemoradiotherapy for advanced head and neck
47 We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC.
48  cancer, or prevention of esophagitis during concurrent chemoradiotherapy for non-small-cell lung can
49  study of induction chemotherapy followed by concurrent chemoradiotherapy for organ preservation in p
50                                              Concurrent chemoradiotherapy has become a widely used me
51                                              Concurrent chemoradiotherapy has been the standard of ca
52 gative (18)F-FDG PET or PET/CT results after concurrent chemoradiotherapy have a high negative predic
53 hedule of induction chemotherapy followed by concurrent chemoradiotherapy have been encouraging, and
54                                              Concurrent chemoradiotherapy improves cancer-related out
55 -intent treatment of locally advanced NSCLC, concurrent chemoradiotherapy improves local control and
56 Limited-stage disease should be treated with concurrent chemoradiotherapy in patients with good perfo
57 ot differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-st
58 9) demonstrated efficacy and tolerability of concurrent chemoradiotherapy in poor-risk stage III non-
59 daily gefitinib with radiation alone or with concurrent chemoradiotherapy in previously untreated pat
60  incorporate these agents with induction and concurrent chemoradiotherapy in stage III NSCLC.
61                Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB NSCLC is feas
62                                Toxicities of concurrent chemoradiotherapy included grade 3 esophagiti
63 pre) was performed at study entry and before concurrent chemoradiotherapy (interim-PET; PETpost).
64 ad and neck squamous cell carcinoma (HNSCC), concurrent chemoradiotherapy is a widely accepted treatm
65                                              Concurrent chemoradiotherapy is associated with a one in
66                                              Concurrent chemoradiotherapy is standard treatment for p
67                                              Concurrent chemoradiotherapy is the standard of care for
68                                              Concurrent chemoradiotherapy is the standard of care in
69                       Enhanced outcomes with concurrent chemoradiotherapy may result from increased d
70        In the patients who received previous concurrent chemoradiotherapy, median overall survival fo
71 of HART, mucosal toxicity, and the fact that concurrent chemoradiotherapy now seems more effective th
72 s more pronounced with the administration of concurrent chemoradiotherapy on study arms 2 and 3 (19%
73 based chemotherapies with or without upfront concurrent chemoradiotherapy or radiotherapy with curati
74 line-based chemotherapies and upfront use of concurrent chemoradiotherapy or radiotherapy.
75  lung cancer (NSCLC) cannot receive standard concurrent chemoradiotherapy owing to the risk of toxic
76 in/etoposide [PE]; three cycles) followed by concurrent chemoradiotherapy (PE plus 45 Gy; 1.5 Gy twic
77 ute mucositis is a dose-limiting toxicity of concurrent chemoradiotherapy regimens for locally advanc
78 to improve patient access to curative intent concurrent chemoradiotherapy regimens.
79 patients seen in their own clinical practice.Concurrent chemoradiotherapy remains central to the trea
80  carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly
81 rvalumab or matching placebo 1-42 days after concurrent chemoradiotherapy, then every 2 weeks up to 1
82  appropriate, standard treatment option, and concurrent chemoradiotherapy therapy is the most widely
83  Chemotherapy soon after surgery followed by concurrent chemoradiotherapy therapy was feasible; toler
84                                       During concurrent chemoradiotherapy, there was no difference in
85                                              Concurrent chemoradiotherapy using twice-daily radiation
86           Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with
87           Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with
88 wer absolute neutrophil count after starting concurrent chemoradiotherapy was associated with higher
89                                              Concurrent chemoradiotherapy was generally well tolerate
90 nosed stage IV oral cavity cancer undergoing concurrent chemoradiotherapy were included.
91 dy included patients with SCCHN who received concurrent chemoradiotherapy with C/P or cisplatin from
92  assigned to arm A, which involved immediate concurrent chemoradiotherapy with carboplatin area under
93 cil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concur
94 therapy with three cycles of TPF followed by concurrent chemoradiotherapy with either docetaxel or ca
95                                              Concurrent chemoradiotherapy with hyperfractionated RT i
96                                              Concurrent chemoradiotherapy with or without surgery are
97  1998, many randomized studies that compared concurrent chemoradiotherapy with radiotherapy alone hav
98  well tolerated with concomitant boost RT or concurrent chemoradiotherapy with weekly CDDP.
99 luated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved su
100 d that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median